We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Hematologic Malignancies
MedXY News
EnglishTag

Hematologic Malignancies

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Cardiovascular Risks of CAR-T Therapy in Older Adults: Insights from US Medicare Data
Cardiologyolder adultsHematologic Malignancies

Cardiovascular Risks of CAR-T Therapy in Older Adults: Insights from US Medicare Data

By MedXY|Sep 19, 2026

Among older adults receiving CAR-T therapy, 5.8% experienced major adverse cardiovascular events (MACE), associated with increased mortality. Pre-existing cardiac conditions heightened risk, underscoring the need for cardiovascular monitori

Evolving Epidemiology and Survival Trends in Myeloproliferative Neoplasms: Insights from SEER 2000-2021
Hematology-OncologysurvivalSEER
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

Evolving Epidemiology and Survival Trends in Myeloproliferative Neoplasms: Insights from SEER 2000-2021

By MedXY|Sep 13, 2026

Analysis of SEER data from 2000-2021 reveals incidence, survival trends, and demographic disparities in US patients with myeloproliferative neoplasms, highlighting improved outcomes particularly in primary myelofibrosis and areas for furthe

Plasma Biomarkers CPVL and PIGR Predict Anthracycline-Induced Cardiotoxicity in Hematologic Cancer Patients
CardiologyHematologic MalignanciesPIGR

Plasma Biomarkers CPVL and PIGR Predict Anthracycline-Induced Cardiotoxicity in Hematologic Cancer Patients

By MedXY|Aug 29, 2026

Baseline plasma levels of CPVL and PIGR correlate with anthracycline-induced systolic dysfunction, offering potential early biomarkers for cardiotoxicity in hematologic malignancy patients undergoing chemotherapy.

Rogocekib Demonstrates Clinical Activity as a First-in-Class CLK Inhibitor in Relapsed or Refractory AML and MDS
Hematology-OncologyAMLHematologic Malignancies

Rogocekib Demonstrates Clinical Activity as a First-in-Class CLK Inhibitor in Relapsed or Refractory AML and MDS

By MedXY|Jan 20, 2026

This Phase 1 study evaluates rogocekib, a novel CDC2-like kinase inhibitor, in patients with relapsed or refractory hematologic malignancies, reporting manageable safety and significant complete remission rates in AML and MDS cohorts, signa

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities